2015 Q1 Form 10-Q Financial Statement
#000119312515187962 Filed on May 14, 2015
Income Statement
| Concept | 2015 Q1 | 2014 Q1 |
|---|---|---|
| Revenue | $0.00 | $0.00 |
| YoY Change | ||
| Cost Of Revenue | ||
| YoY Change | ||
| Gross Profit | ||
| YoY Change | ||
| Gross Profit Margin | ||
| Selling, General & Admin | $970.0K | $800.0K |
| YoY Change | 21.25% | 471.43% |
| % of Gross Profit | ||
| Research & Development | $1.136M | $444.3K |
| YoY Change | 155.79% | 195.73% |
| % of Gross Profit | ||
| Depreciation & Amortization | $1.252K | $0.00 |
| YoY Change | ||
| % of Gross Profit | ||
| Operating Expenses | $1.136M | $444.3K |
| YoY Change | 155.79% | 195.73% |
| Operating Profit | -$2.109M | -$1.245M |
| YoY Change | 69.37% | 327.02% |
| Interest Expense | $28.02K | $113.2K |
| YoY Change | -75.25% | 635.06% |
| % of Operating Profit | ||
| Other Income/Expense, Net | -$28.02K | $1.647M |
| YoY Change | -101.7% | -144.71% |
| Pretax Income | -$2.140M | $400.0K |
| YoY Change | -635.0% | -110.08% |
| Income Tax | $0.00 | $0.00 |
| % Of Pretax Income | 0.0% | |
| Net Earnings | -$2.137M | $401.8K |
| YoY Change | -631.78% | -110.11% |
| Net Earnings / Revenue | ||
| Basic Earnings Per Share | -$0.32 | -$0.04 |
| Diluted Earnings Per Share | -$0.32 | -$4.04 |
| COMMON SHARES | ||
| Basic Shares Outstanding | 6.668M shares | 327.4K shares |
| Diluted Shares Outstanding | 6.668M shares | 439.0K shares |
Balance Sheet
| Concept | 2015 Q1 | 2014 Q1 |
|---|---|---|
| SHORT-TERM ASSETS | ||
| Cash & Short-Term Investments | $15.70M | $2.100M |
| YoY Change | 647.62% | |
| Cash & Equivalents | $15.72M | $2.146M |
| Short-Term Investments | ||
| Other Short-Term Assets | $200.0K | $0.00 |
| YoY Change | ||
| Inventory | ||
| Prepaid Expenses | ||
| Receivables | ||
| Other Receivables | ||
| Total Short-Term Assets | $15.90M | $2.155M |
| YoY Change | 637.61% | |
| LONG-TERM ASSETS | ||
| Property, Plant & Equipment | $13.18K | |
| YoY Change | ||
| Goodwill | ||
| YoY Change | ||
| Intangibles | ||
| YoY Change | ||
| Long-Term Investments | ||
| YoY Change | ||
| Other Assets | $0.00 | $700.0K |
| YoY Change | -100.0% | |
| Total Long-Term Assets | $33.18K | $735.2K |
| YoY Change | -95.49% | |
| TOTAL ASSETS | ||
| Total Short-Term Assets | $15.90M | $2.155M |
| Total Long-Term Assets | $33.18K | $735.2K |
| Total Assets | $15.93M | $2.891M |
| YoY Change | 451.15% | |
| SHORT-TERM LIABILITIES | ||
| YoY Change | ||
| Accounts Payable | $406.1K | $166.0K |
| YoY Change | 144.72% | |
| Accrued Expenses | $436.2K | $133.1K |
| YoY Change | 227.76% | |
| Deferred Revenue | ||
| YoY Change | ||
| Short-Term Debt | $0.00 | $200.0K |
| YoY Change | -100.0% | |
| Long-Term Debt Due | $193.9K | $232.6K |
| YoY Change | -16.67% | |
| Total Short-Term Liabilities | $1.036M | $691.5K |
| YoY Change | 49.84% | |
| LONG-TERM LIABILITIES | ||
| Long-Term Debt | $1.069M | $972.4K |
| YoY Change | 9.88% | |
| Other Long-Term Liabilities | $600.0K | |
| YoY Change | ||
| Total Long-Term Liabilities | $1.069M | $972.4K |
| YoY Change | 9.88% | |
| TOTAL LIABILITIES | ||
| Total Short-Term Liabilities | $1.036M | $691.5K |
| Total Long-Term Liabilities | $1.069M | $972.4K |
| Total Liabilities | $2.105M | $4.027M |
| YoY Change | -47.74% | |
| SHAREHOLDERS EQUITY | ||
| Retained Earnings | -$48.65M | |
| YoY Change | ||
| Common Stock | $6.890K | |
| YoY Change | ||
| Preferred Stock | ||
| YoY Change | ||
| Treasury Stock (at cost) | ||
| YoY Change | ||
| Treasury Stock Shares | ||
| Shareholders Equity | $13.83M | -$39.65M |
| YoY Change | ||
| Total Liabilities & Shareholders Equity | $15.93M | $2.891M |
| YoY Change | 451.15% |
Cashflow Statement
| Concept | 2015 Q1 | 2014 Q1 |
|---|---|---|
| OPERATING ACTIVITIES | ||
| Net Income | -$2.137M | $401.8K |
| YoY Change | -631.78% | -110.11% |
| Depreciation, Depletion And Amortization | $1.252K | $0.00 |
| YoY Change | ||
| Cash From Operating Activities | -$1.840M | -$1.060M |
| YoY Change | 73.58% | 253.33% |
| INVESTING ACTIVITIES | ||
| Capital Expenditures | $1.441K | $0.00 |
| YoY Change | ||
| Acquisitions | ||
| YoY Change | ||
| Other Investing Activities | ||
| YoY Change | ||
| Cash From Investing Activities | $0.00 | $0.00 |
| YoY Change | ||
| FINANCING ACTIVITIES | ||
| Cash Dividend Paid | ||
| YoY Change | ||
| Common Stock Issuance & Retirement, Net | $9.039M | |
| YoY Change | ||
| Debt Paid & Issued, Net | ||
| YoY Change | ||
| Cash From Financing Activities | 9.040M | -50.00K |
| YoY Change | -18180.0% | -106.67% |
| NET CHANGE | ||
| Cash From Operating Activities | -1.840M | -1.060M |
| Cash From Investing Activities | 0.000 | 0.000 |
| Cash From Financing Activities | 9.040M | -50.00K |
| Net Change In Cash | 7.200M | -1.110M |
| YoY Change | -748.65% | -346.67% |
| FREE CASH FLOW | ||
| Cash From Operating Activities | -$1.840M | -$1.060M |
| Capital Expenditures | $1.441K | $0.00 |
| Free Cash Flow | -$1.841M | -$1.060M |
| YoY Change | 73.72% | 253.33% |
Facts In Submission
| Frame | Concept Type | Concept / XBRL Key | Value | Unit |
|---|---|---|---|---|
| CY2015Q2 | dei |
Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
|
9590021 | shares |
| CY2014Q1 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
2145621 | |
| CY2015Q1 | us-gaap |
Common Stock Shares Issued
CommonStockSharesIssued
|
6890021 | shares |
| CY2015Q1 | us-gaap |
Common Stock Shares Outstanding
CommonStockSharesOutstanding
|
6890021 | shares |
| CY2015Q1 | us-gaap |
Common Stock Shares Authorized
CommonStockSharesAuthorized
|
150000000 | shares |
| CY2015Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
|
239369 | shares |
| CY2015Q1 | us-gaap |
Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
|
0 | shares |
| CY2015Q1 | us-gaap |
Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
|
0.001 | |
| CY2015Q1 | us-gaap |
Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
|
15000000 | shares |
| CY2015Q1 | us-gaap |
Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
|
0.001 | |
| CY2015Q1 | us-gaap |
Preferred Stock Shares Issued
PreferredStockSharesIssued
|
0 | shares |
| CY2015Q1 | us-gaap |
Preferred Stock Value
PreferredStockValue
|
||
| CY2015Q1 | us-gaap |
Liabilities Current
LiabilitiesCurrent
|
1036168 | |
| CY2015Q1 | us-gaap |
Common Stock Value
CommonStockValue
|
6890 | |
| CY2015Q1 | us-gaap |
Commitments And Contingencies
CommitmentsAndContingencies
|
||
| CY2015Q1 | us-gaap |
Accounts Payable Current
AccountsPayableCurrent
|
406145 | |
| CY2015Q1 | us-gaap |
Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
|
-48648156 | |
| CY2015Q1 | us-gaap |
Long Term Debt Current
LongTermDebtCurrent
|
193866 | |
| CY2015Q1 | us-gaap |
Accrued Liabilities Current
AccruedLiabilitiesCurrent
|
436157 | |
| CY2015Q1 | us-gaap |
Stockholders Equity
StockholdersEquity
|
13826670 | |
| CY2014Q4 | us-gaap |
Commitments And Contingencies
CommitmentsAndContingencies
|
||
| CY2015Q1 | us-gaap |
Long Term Debt Noncurrent
LongTermDebtNoncurrent
|
1068515 | |
| CY2015Q1 | us-gaap |
Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
|
15931353 | |
| CY2015Q1 | us-gaap |
Additional Paid In Capital
AdditionalPaidInCapital
|
62467936 | |
| CY2015Q1 | us-gaap |
Liabilities
Liabilities
|
2104683 | |
| CY2015Q1 | us-gaap |
Liabilities Fair Value Disclosure
LiabilitiesFairValueDisclosure
|
0 | |
| CY2015Q1 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
15721097 | |
| CY2015Q1 | us-gaap |
Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
|
3863472 | |
| CY2015Q1 | us-gaap |
Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
|
13182 | |
| CY2015Q1 | us-gaap |
Assets Fair Value Disclosure
AssetsFairValueDisclosure
|
0 | |
| CY2015Q1 | us-gaap |
Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
|
177074 | |
| CY2015Q1 | us-gaap |
Debt Instrument Unamortized Discount
DebtInstrumentUnamortizedDiscount
|
133453 | |
| CY2015Q1 | us-gaap |
Assets
Assets
|
15931353 | |
| CY2015Q1 | us-gaap |
Assets Current
AssetsCurrent
|
15898171 | |
| CY2015Q1 | aldx |
Deferred Offering Costs Noncurrent
DeferredOfferingCostsNoncurrent
|
20000 | |
| CY2013Q4 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
3262354 | |
| CY2014Q4 | us-gaap |
Common Stock Shares Issued
CommonStockSharesIssued
|
6890021 | shares |
| CY2014Q4 | us-gaap |
Common Stock Shares Outstanding
CommonStockSharesOutstanding
|
6890021 | shares |
| CY2014Q4 | us-gaap |
Common Stock Shares Authorized
CommonStockSharesAuthorized
|
150000000 | shares |
| CY2014Q4 | us-gaap |
Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
|
0 | shares |
| CY2014Q4 | us-gaap |
Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
|
0.001 | |
| CY2014Q4 | us-gaap |
Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
|
15000000 | shares |
| CY2014Q4 | us-gaap |
Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
|
0.001 | |
| CY2014Q4 | us-gaap |
Preferred Stock Shares Issued
PreferredStockSharesIssued
|
0 | shares |
| CY2014Q4 | us-gaap |
Preferred Stock Value
PreferredStockValue
|
||
| CY2014Q4 | us-gaap |
Liabilities Current
LiabilitiesCurrent
|
1327564 | |
| CY2014Q4 | us-gaap |
Common Stock Value
CommonStockValue
|
5565 | |
| CY2014Q4 | us-gaap |
Accounts Payable Current
AccountsPayableCurrent
|
341294 | |
| CY2014Q4 | us-gaap |
Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
|
-46511597 | |
| CY2014Q4 | us-gaap |
Long Term Debt Current
LongTermDebtCurrent
|
77546 | |
| CY2014Q4 | us-gaap |
Accrued Liabilities Current
AccruedLiabilitiesCurrent
|
908724 | |
| CY2014Q4 | us-gaap |
Stockholders Equity
StockholdersEquity
|
6284058 | |
| CY2014Q4 | us-gaap |
Long Term Debt Noncurrent
LongTermDebtNoncurrent
|
1175481 | |
| CY2014Q4 | us-gaap |
Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
|
8787103 | |
| CY2014Q4 | us-gaap |
Additional Paid In Capital
AdditionalPaidInCapital
|
52790090 | |
| CY2014Q4 | us-gaap |
Liabilities
Liabilities
|
2503045 | |
| CY2014Q4 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
8527304 | |
| CY2014Q4 | us-gaap |
Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
|
12993 | |
| CY2014Q4 | us-gaap |
Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
|
232568 | |
| CY2014Q4 | us-gaap |
Assets
Assets
|
8787103 | |
| CY2014Q4 | us-gaap |
Assets Current
AssetsCurrent
|
8759872 | |
| CY2014Q4 | aldx |
Deferred Offering Costs Noncurrent
DeferredOfferingCostsNoncurrent
|
14238 | |
| CY2015Q1 | us-gaap |
Share Price
SharePrice
|
20.00 | |
| CY2014Q1 | aldx |
Deferred Offering Costs Paid By Cash
DeferredOfferingCostsPaidByCash
|
52841 | |
| CY2014Q1 | aldx |
Incremental Common Shares Attributable To Stock Options
IncrementalCommonSharesAttributableToStockOptions
|
0 | shares |
| CY2014Q1 | aldx |
Deferred Offering Costs Not Yet Paid
DeferredOfferingCostsNotYetPaid
|
209896 | |
| CY2014Q1 | us-gaap |
Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
|
-1773152 | |
| CY2015Q1 | us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Expiration Period
SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
|
P10Y | |
| CY2015Q1 | us-gaap |
Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
|
9.50 | |
| CY2015Q1 | us-gaap |
Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights
ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
|
1100000 | shares |
| CY2015Q1 | us-gaap |
Sale Of Stock Price Per Share
SaleOfStockPricePerShare
|
7.00 | |
| CY2015Q1 | us-gaap |
Share Price
SharePrice
|
20.00 | |
| CY2015Q1 | us-gaap |
Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
|
0.125 | |
| CY2015Q1 | us-gaap |
Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights
ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
|
211528 | shares |
| CY2015Q1 | us-gaap |
Sale Of Stock Price Per Share
SaleOfStockPricePerShare
|
9.33 | |
| CY2015Q1 | us-gaap |
Sale Of Stock Number Of Shares Issued In Transaction
SaleOfStockNumberOfSharesIssuedInTransaction
|
1100000 | shares |
| CY2015Q1 | us-gaap |
Proceeds From Issuance Of Private Placement
ProceedsFromIssuanceOfPrivatePlacement
|
7100000 | |
| CY2015Q1 | aldx |
Expiration Of Warrant
ExpirationOfWarrant
|
P3Y | |
| CY2015Q1 | aldx |
Redemption Price Of Warrants
RedemptionPriceOfWarrants
|
0.001 | |
| CY2015Q1 | aldx |
Average Trading Volume Of Common Stock
AverageTradingVolumeOfCommonStock
|
50000 | shares |
| CY2015Q1 | invest |
Investment Warrants Exercise Price
InvestmentWarrantsExercisePrice
|
9.50 | |
| CY2015Q1 | us-gaap |
Sale Of Stock Number Of Shares Issued In Transaction
SaleOfStockNumberOfSharesIssuedInTransaction
|
211528 | shares |
| CY2015Q1 | us-gaap |
Proceeds From Issuance Of Private Placement
ProceedsFromIssuanceOfPrivatePlacement
|
2000000 | |
| CY2015Q1 | aldx |
Expiration Of Warrant
ExpirationOfWarrant
|
P3Y | |
| CY2015Q1 | aldx |
Redemption Price Of Warrants
RedemptionPriceOfWarrants
|
0.001 | |
| CY2015Q1 | aldx |
Average Trading Volume Of Common Stock
AverageTradingVolumeOfCommonStock
|
50000 | shares |
| CY2014Q1 | us-gaap |
Earnings Per Share Diluted
EarningsPerShareDiluted
|
-4.04 | |
| CY2014Q1 | us-gaap |
Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
|
-1063892 | |
| CY2014Q1 | us-gaap |
Incremental Common Shares Attributable To Call Options And Warrants
IncrementalCommonSharesAttributableToCallOptionsAndWarrants
|
111610 | shares |
| CY2014Q1 | us-gaap |
Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
|
438975 | shares |
| CY2014Q1 | us-gaap |
Earnings Per Share Basic
EarningsPerShareBasic
|
-0.04 | |
| CY2014Q1 | us-gaap |
Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
|
917219 | shares |
| CY2014Q1 | us-gaap |
Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
|
327365 | shares |
| CY2014Q1 | us-gaap |
Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
|
1329 | |
| CY2014Q1 | us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
-1244924 | |
| CY2014Q1 | us-gaap |
Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
|
-1759915 | |
| CY2014Q1 | us-gaap |
Nonoperating Income Expense
NonoperatingIncomeExpense
|
1646697 | |
| CY2014Q1 | us-gaap |
Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
|
-13237 | |
| CY2014Q1 | us-gaap |
Net Income Loss
NetIncomeLoss
|
401773 | |
| CY2014Q1 | us-gaap |
Investment Income Interest
InvestmentIncomeInterest
|
3 | |
| CY2014Q1 | us-gaap |
Interest Paid
InterestPaid
|
22682 | |
| CY2014Q1 | us-gaap |
Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
|
365686 | |
| CY2014Q1 | us-gaap |
Interest Expense
InterestExpense
|
113221 | |
| CY2014Q1 | us-gaap |
Research And Development Expense
ResearchAndDevelopmentExpense
|
444278 | |
| CY2014Q1 | us-gaap |
Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
|
-1116733 | |
| CY2014Q1 | us-gaap |
Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
|
-1759915 | |
| CY2014Q1 | us-gaap |
Temporary Equity Accretion To Redemption Value Adjustment
TemporaryEquityAccretionToRedemptionValueAdjustment
|
191568 | |
| CY2014Q1 | us-gaap |
Increase Decrease In Notes Payable Related Parties
IncreaseDecreaseInNotesPayableRelatedParties
|
2607 | |
| CY2014Q1 | us-gaap |
Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
|
-52841 | |
| CY2014Q1 | us-gaap |
Undistributed Earnings Loss Allocated To Participating Securities Basic
UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic
|
223442 | |
| CY2014Q1 | us-gaap |
Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
|
87980 | |
| CY2014Q1 | us-gaap |
Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
|
15198 | |
| CY2014Q1 | us-gaap |
General And Administrative Expense
GeneralAndAdministrativeExpense
|
800646 | |
| CY2014Q1 | us-gaap |
Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
|
-175892 | |
| CY2014Q1 | us-gaap |
Share Based Compensation
ShareBasedCompensation
|
365686 | |
| CY2015Q1 | us-gaap |
Basis Of Accounting
BasisOfAccounting
|
<div> <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0"> <tr> <td valign="top" width="4%" align="left"><b>2.</b></td> <td valign="top" align="left"><b>BASIS OF PRESENTATION</b></td> </tr> </table> <!-- xbrl,body --> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 4%; MARGIN-TOP: 6pt"> The accompanying interim unaudited condensed financial statements and related disclosures are unaudited and have been prepared in accordance with U.S. generally accepted accounting principles (GAAP) for interim financial information and the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all the information and footnotes required by GAAP for complete financial statements and should be read in conjunction with the Company’s financial statements and related footnotes for the year ended December 31, 2014 included in the Company’s Annual Report on Form 10 -K for the year ended December 31, 2014, which was filed with the Securities and Exchange Commission on March 23, 2015. The financial information as of March 31, 2015, the three months ended March 31, 2015 and 2014 is unaudited, but in the opinion of management, all adjustments, consisting only of normal recurring adjustments, considered necessary for a fair presentation of the financial position, results of operations and cash flows at the dates and for the periods presented of the results of these interim periods have been included. The balance sheet data as of December 31, 2014 was derived from audited financial statements. The results of the Company’s operations for any interim period are not necessarily indicative of the results that may be expected for any other interim period or for a full fiscal year.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 4%; MARGIN-TOP: 6pt"> On January 14, 2015, the Company sold, in a private placement, an aggregate of approximately 1.1 million shares of common stock at a price of $7.00 per share. Investors received warrants to purchase up to approximately 1.1 million shares of common stock at an exercise price of $9.50. The warrants will expire 3 years from the date of issuance. The warrants do not include a net-exercise feature. The warrants may be redeemed by the Company at a price of $0.001 per share upon notice to the holders in the event that the closing bid for Aldeyra’s common stock for each of the fifteen consecutive trading days prior to such redemption is at least $20.00 per share and the average trading volume of Aldeyra’s common stock during such period is 50,000 shares per day. Following Aldeyra’s notification to the warrant holders of its exercise of the redemption right under the warrants, each warrant holder will have the option to exercise their warrants prior to the redemption date rather than having them redeemed. The Company raised approximately $7.1 million in net proceeds in the private placement of common stock and warrants.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 4%; MARGIN-TOP: 6pt"> On January 21, 2015, in a subsequent private placement, the Company sold an aggregate of 211,528 shares of common stock at a price of $9.33 per share and a warrant to purchase up to 211,528 shares of common stock at a price of $0.125 per share subject to the warrant. The exercise price of the warrant is $9.50 per share. The warrant will expire 3 years from the date of issuance. The warrant does not include a net-exercise feature. The warrant may be redeemed by the Company at a price of $0.001 per share upon notice to the holder thereof in the event that the closing bid for Aldeyra’s common stock for each of the fifteen consecutive trading days prior to such redemption is at least $20.00 per share and the average trading volume of Aldeyra’s common stock during such period is at least 50,000 shares per day. Following Aldeyra’s notification to the warrant holder of its exercise of the redemption right under the warrant, the warrant holder will have the option to exercise the warrant prior to the redemption date rather than having it redeemed. The Company raised approximately $2.0 million in net proceeds in the private placement of common stock and a warrant to purchase common stock.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 4%; MARGIN-TOP: 6pt"> In addition, the Company raised $18.8 million, after deducting underwriting discounts and commissions and other offering expenses, on May 13, 2015, through the issuance and sale of 2,700,000 shares of common stock in a follow-on public offering.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 4%; MARGIN-TOP: 6pt"> The Company’s management believes that its currently available resources, including funds obtained from the May 2015 follow-on public offering and amounts potentially available under its credit facility Note 5, will provide sufficient funds to enable the Company to meet its expected obligations through approximately the end of 2017 based on the Company’s current business plan. However, these amounts will not be sufficient for the Company to commercialize its product candidates or conduct any substantial, additional development requirements requested by the FDA. Additional funding may not be available to the Company on acceptable terms, or at all. If the Company is unable to secure additional capital, or meet financial covenants that could be implemented under the Company’s term loans in certain circumstances, it will be required to significantly decrease the amount of planned expenditures, and may be required to cease operations.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 4%; MARGIN-TOP: 6pt"> Curtailment of operations would cause significant delays in the Company’s efforts to introduce its products to market, which is critical to the realization of its business plan and the future operations of the Company.</p> <p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 1px; MARGIN-TOP: 18px">  </p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 4%; MARGIN-TOP: 0pt"> <b><i>Use of estimates</i></b></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 4%; MARGIN-TOP: 6pt"> The preparation of financial statements in conformity with GAAP requires management to make estimates that affect the reported amounts of assets and liabilities at the date of the financial statements, disclosure of contingent assets and liabilities, and the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates.</p> </div> | |
| CY2015Q1 | dei |
Trading Symbol
TradingSymbol
|
ALDX | |
| CY2014Q1 | aldx |
Change In Fair Value Of Warrant Liabilities Purchase Right And Warrant Purchase Rights
ChangeInFairValueOfWarrantLiabilitiesPurchaseRightAndWarrantPurchaseRights
|
-1759915 | |
| CY2015Q1 | us-gaap |
Earnings Per Share Diluted
EarningsPerShareDiluted
|
-0.32 | |
| CY2015Q1 | dei |
Document Type
DocumentType
|
10-Q | |
| CY2015Q1 | dei |
Entity Registrant Name
EntityRegistrantName
|
ALDEYRA THERAPEUTICS, INC. | |
| CY2015Q1 | dei |
Entity Filer Category
EntityFilerCategory
|
Smaller Reporting Company | |
| CY2015Q1 | us-gaap |
Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
|
P4Y9M22D | |
| CY2015Q1 | us-gaap |
Nature Of Operations
NatureOfOperations
|
<div> <table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" border="0" cellpadding="0" cellspacing="0" width="100%"> <tr> <td width="4%" valign="top" align="left"><b>1.</b></td> <td align="left" valign="top"><b>NATURE OF BUSINESS</b></td> </tr> </table> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"> Aldeyra Therapeutics, Inc. (the Company or Aldeyra) was incorporated in the state of Delaware. The Company is developing a treatment for diseases thought to be related to high levels of free aldehydes, naturally occurring pro-inflammatory toxins.</p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"> The Company’s principal activities to date include raising capital and research and development activities.</p> </div> | |
| CY2015Q1 | us-gaap |
Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
|
-1843864 | |
| CY2015Q1 | us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Purchase Price Of Common Stock Percent
SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent
|
1.00 | pure |
| CY2015Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Number Of Additional Shares Authorized
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
|
871571 | shares |
| CY2015Q1 | us-gaap |
Use Of Estimates
UseOfEstimates
|
<div> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 4%; MARGIN-TOP: 0pt"> <b><i>Use of estimates</i></b></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 4%; MARGIN-TOP: 6pt"> The preparation of financial statements in conformity with GAAP requires management to make estimates that affect the reported amounts of assets and liabilities at the date of the financial statements, disclosure of contingent assets and liabilities, and the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates.</p> </div> | |
| CY2015Q1 | dei |
Document Period End Date
DocumentPeriodEndDate
|
2015-03-31 | |
| CY2015Q1 | us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
|
P8Y10M24D | |
| CY2015Q1 | dei |
Amendment Flag
AmendmentFlag
|
false | |
| CY2015Q1 | dei |
Current Fiscal Year End Date
CurrentFiscalYearEndDate
|
--12-31 | |
| CY2015Q1 | dei |
Document Fiscal Year Focus
DocumentFiscalYearFocus
|
2015 | |
| CY2015Q1 | us-gaap |
Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
|
6667519 | shares |
| CY2015Q1 | us-gaap |
Earnings Per Share Basic
EarningsPerShareBasic
|
-0.32 | |
| CY2015Q1 | us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
|
P7Y9M7D | |
| CY2015Q1 | dei |
Entity Central Index Key
EntityCentralIndexKey
|
0001341235 | |
| CY2015Q1 | us-gaap |
Interest Expense
InterestExpense
|
28024 | |
| CY2015Q1 | dei |
Document Fiscal Period Focus
DocumentFiscalPeriodFocus
|
Q1 | |
| CY2015Q1 | us-gaap |
Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
|
2258640 | shares |
| CY2015Q1 | us-gaap |
Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
|
6667519 | shares |
| CY2015Q1 | us-gaap |
Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
|
9039098 | |
| CY2015Q1 | us-gaap |
Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
|
-2136559 | |
| CY2015Q1 | us-gaap |
Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
|
-55494 | |
| CY2015Q1 | us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
-2108535 | |
| CY2015Q1 | us-gaap |
Nonoperating Income Expense
NonoperatingIncomeExpense
|
-28024 | |
| CY2015Q1 | us-gaap |
Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
|
1441 | |
| CY2015Q1 | us-gaap |
Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
|
-2136559 | |
| CY2015Q1 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-2136559 | |
| CY2015Q1 | us-gaap |
Interest Paid
InterestPaid
|
18320 | |
| CY2015Q1 | us-gaap |
Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
|
640073 | |
| CY2015Q1 | us-gaap |
Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
|
640073 | |
| CY2015Q1 | us-gaap |
Research And Development Expense
ResearchAndDevelopmentExpense
|
1136434 | |
| CY2015Q1 | us-gaap |
Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
|
7193793 | |
| CY2015Q1 | us-gaap |
Income Tax Expense Benefit
IncomeTaxExpenseBenefit
|
0 | |
| CY2015Q1 | us-gaap |
Depreciation
Depreciation
|
1252 | |
| CY2015Q1 | us-gaap |
Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
|
9039098 | |
| CY2015Q1 | us-gaap |
Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
|
9039098 | |
| CY2015Q1 | us-gaap |
Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
|
9354 | |
| CY2015Q1 | us-gaap |
Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
|
-478329 | |
| CY2015Q1 | us-gaap |
Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
|
-1441 | |
| CY2015Q1 | us-gaap |
General And Administrative Expense
GeneralAndAdministrativeExpense
|
972101 | |
| CY2015Q1 | us-gaap |
Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
|
64851 | |
| CY2015Q1 | us-gaap |
Share Based Compensation
ShareBasedCompensation
|
640073 | |
| CY2015Q1 | aldx |
Number Of Stock Incentive Plans
NumberOfStockIncentivePlans
|
3 | Plan |
| CY2015Q1 | aldx |
Deferred Offering Costs Not Yet Paid
DeferredOfferingCostsNotYetPaid
|
20000 | |
| CY2015Q1 | aldx |
Lines Of Credit Facility Maturity Period
LinesOfCreditFacilityMaturityPeriod
|
2018-11 | |
| CY2015Q1 | aldx |
Deferred Tax Assets Valuation Allowance Percentage
DeferredTaxAssetsValuationAllowancePercentage
|
1.00 | pure |
| CY2015Q1 | aldx |
Number Of Incentive Plans
NumberOfIncentivePlans
|
3 | Incentive_Plan |
